Briacell TherapeuticsBCTX
13F holders, Q2 2026 (June 30)18holders +2
3new positions
1sold out
$3.24avg. 13F price*
At the end of Q2 2026, 18 institutions reported holding Briacell Therapeutics Corp. (BCTX) in their 13F filings, up 2 from Q1 2026. 3 opened new positions and 1 sold out. The largest holders were Cable Car Capital, LP ($703K), Sabby Management, LLC ($262K) and Iridian Asset Management LLC ($211K).
- Company
- Briacell Therapeutics Corp.
- CUSIP
- 107930307
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $199K |
| Exits | 1 | $0 |
All 13F filers, Q1 2026 → Q2 2026: 101,580 shares bought and 2,003 shares sold, net +99,577 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 18 holders
| Cable Car Capital, LP | 0.02% | No change | 216,821 | $703K |
| Sabby Management, LLC | 2.21% | Add +9.2% | 80,721 | $262K |
| Iridian Asset Management LLC | 0.07% | No change | 65,000 | $211K |
| UBS Group AG | 0.00% | Add +278.1% | 43,642 | $141K |
| HRT Financial LP | 0.00% | New | 34,904 | $113K |
| Jane Street Group, LLC | 0.00% | New | 26,515 | $86K |
| LuminArx Capital Management LP | 0.03% | No change | 15,000 | $49K |
| National Bank of Canada | 0.00% | Add +124.8% | 1,803 | $6K |
| Morgan Stanley | 0.00% | Reduce -65.8% | 1,033 | $3K |
| Federation des caisses Desjardins du Quebec | 0.00% | Reduce -1.1% | 450 | $1K |
| Royal Bank of Canada | 0.00% | Add +189.0% | 289 | $1K |
| Allworth Financial LP | 0.00% | No change | 100 | $324 |
| Ssa Swiss Advisors AG | 0.00% | New | 37 | $121 |
| Caitong International Asset Management Co., Ltd | 0.00% | Add +385.7% | 34 | $110 |
| TD Waterhouse Canada Inc. | 0.00% | No change | 19 | $66 |
| Group One Trading LLC | 0.00% | No change | 16 | $52 |
| HHM Wealth Advisors, LLC | 0.00% | No change | 6 | $20 |
| Wells Fargo & Company | 0.00% | No change | 1 | $3 |
"% of holder's portfolio" is BCTX's weight in each manager's 13F, not the share of Briacell Therapeutics Corp. the manager owns.